Skip to NavigationSkip to content

Joseph Zakrzewski, executive chairman, Amarin

Published on: 13/01/10

Dublin-headquartered biotech Amarin has appointed Joseph Zakrzewski executive chairman.

He is currently the chief executive of Xcellerex, a Massachusetts-based biotechnology company, and serves on the board of directors of Insulet Corporation and is chairman of the boards of directors for Promedior and Zelos Therapeutics.

Zakrzewski has more than 20 years of industry experience, including making significant contributions to Reliant Pharmaceuticals as chief operating officer in the lead up to its 2007 acquisition by GlaxoSmithKline.

He has also spent 17 years at Lilly in a variety of roles, including VP of corporate business development where he had global responsibility for licensing activities.

Commenting on his appointment Zakrzewski said: “Having reviewed Amarin’s compelling business plan and cardiovascular development strategy, I am pleased to be joining the company’s board of directors as executive chairman.

“With AMR101 poised to enter phase III clinical trials, and the combination of the company’s recent financing by top-tier investors, the composition of its board and the high quality management team, I believe this is a unique opportunity to create value for Amarin shareholders.”

Previous chairman Thomas Lynch will continue to serve as a member of Amarin’s board of directors.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches